Last reviewed · How we verify
Nifedipine GTIS
At a glance
| Generic name | Nifedipine GTIS |
|---|---|
| Also known as | Nifedipine |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Oedema peripheral
- Oedema
- Dizziness
- Headache
- Nasopharyngitis
- Upper respiratory tract infection
- Fatigue
Key clinical trials
- Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NA)
- PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA. (PHASE3)
- 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Safest Choice of Antihypertensive Regimen for Postpartum Hypertension (PHASE3)
- Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NA)
- Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifedipine GTIS CI brief — competitive landscape report
- Nifedipine GTIS updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI